DRAVP ID  DRAVPa2333

Peptide Name   Sequence 84 from CN118620043A

Sequence  RVRALYFPA

Sequence Length  9

Source  human

Target Organism  HBV

Patent Type  Patent Application

Publication Date  2024-09-10

Patent No  CN118620040A

Family Info  CN 114478711 A, CN 118580321 A, CN 118580322 A, CN 118620040 A, CN 114478711 B, CN 119039403 A

Patent Title  Antigen peptide aiming at hepatitis B virus

Comment 

Abstract  The invention relates to an antigen peptide aiming at hepatitis B virus, which is synthesized by combining human leukocyte antigen haplotypes in I-type molecules of different major histocompatibility complexes and using a biological information prediction method on the basis of an amino acid sequence of hepatitis B virus coding protein. The antigen peptide comprises at least one of amino acid sequences as shown in SEQ ID NO: 1-127. According to the antigen peptide disclosed by the invention, the individualized effectiveness of the antigen peptide is verified by utilizing an immune experiment in a human body experiment, so that the blank of the individualized antigen peptide in liver cancer treatment is filled up; the antigen peptide disclosed by the invention can be used for remarkably activating T cells specifically aiming at HBV (Hepatitis B Virus) of a human body and increasing the killing ability of the T cells on HBV-infected liver cancer cells, and the antigen peptide can be applied to standardized individualized HBV-related liver cancer immunotherapy through large-scale synthesis.